We are live on ! Find out more
KITE

Kite Pharma, Inc.
KITE

Delisted

KITE was delisted on the 2nd of October, 2017.

195 hedge funds and large institutions have $2.15B invested in Kite Pharma, Inc. in 2016 Q3 according to their latest regulatory filings, with 43 funds opening new positions, 82 increasing their positions, 42 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

126% more first-time investments, than exits

New positions opened: 43 | Existing positions closed: 19

95% more repeat investments, than reductions

Existing positions increased: 82 | Existing positions reduced: 42

67% more funds holding in top 10

Funds holding in top 10: 35 (+2)

14% more capital invested

Capital invested by funds: $1.88B → $2.15B (+$267M)

13% more funds holding

Funds holding: 173195 (+22)

23% less call options, than puts

Call options by funds: $68.3M | Put options by funds: $88.7M

Holders
195
Holders Change
+22
Holders Change %
+12.72%
% of All Funds
5.2%
Holding in Top 10
5
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+66.67%
% of All Funds
0.13%
New
43
Increased
82
Reduced
42
Closed
19
Calls
$68.3M
Puts
$88.7M
Net Calls
-$20.4M
Net Calls Change
-$39.9M
Name Holding Trade Value Shares
Change
Change in
Stake
Norges Bank
26
Norges Bank
Norway
$20M +$2.92M +52,380 +16%
American Century Companies
27
American Century Companies
Missouri
$19.3M +$2.56M +46,011 +15%
Geode Capital Management
28
Geode Capital Management
Massachusetts
$17.9M +$343K +6,148 +2%
AG
29
Artal Group
Luxembourg
$17.6M -$557K -10,000 -3%
PAMU
30
Pictet Asset Management (UK)
United Kingdom
$14.7M +$4.46M +80,052 +44%
CBA
31
Coastal Bridge Advisors
Connecticut
$14M
FCM
32
Frontier Capital Management
Massachusetts
$13.3M +$1.07M +19,117 +9%
DP
33
DSAM Partners
United Kingdom
$12.2M -$728K -13,073 -6%
Deutsche Bank
34
Deutsche Bank
Germany
$11.7M +$4.11M +73,756 +54%
Bank of New York Mellon
35
Bank of New York Mellon
New York
$11.6M -$148K -2,656 -1%
MIFH
36
Migdal Insurance & Financial Holdings
Israel
$11.2M
Charles Schwab
37
Charles Schwab
California
$9.19M +$725K +13,020 +9%
EAM
38
Eventide Asset Management
Massachusetts
$8.3M
BIM
39
BlackRock Investment Management
Delaware
$8.23M +$61K +1,094 +0.7%
CS
40
Candriam SCA
Luxembourg
$6.68M -$3.34M -60,000 -33%
SAM
41
Sectoral Asset Management
Quebec, Canada
$6.5M +$6.48M +116,326 New
Jennison Associates
42
Jennison Associates
New York
$6.42M +$6.4M +114,879 New
TA
43
Teachers Advisors
New York
$6.38M +$799K +14,348 +14%
O
44
OppenheimerFunds
New York
$6.02M +$6.01M +107,800 New
Zurich Cantonal Bank
45
Zurich Cantonal Bank
Switzerland
$5.95M +$48.5K +871 +0.8%
CS
46
Credit Suisse
Switzerland
$5.29M +$1.46M +26,197 +38%
DekaBank Deutsche Girozentrale
47
DekaBank Deutsche Girozentrale
Germany
$5.04M -$2.95M -53,000 -37%
RPAM
48
Rhenman & Partners Asset Management
Sweden
$5.03M +$1.11M +20,000 +29%
CC
49
Casdin Capital
New York
$5.03M +$975K +17,500 +24%
California Public Employees Retirement System
50
California Public Employees Retirement System
California
$4.85M -$334K -6,000 -6%

KITE Hedge Fund Activity: Q3 2016 in Review

195 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Kite Pharma, Inc. (KITE) for Q3 2016, worth a combined $2.15B — up 14% from $1.88B a quarter earlier.

Buyers outnumbered sellers: 43 funds opened new KITE positions and 19 closed out — a net gain of 24 holders — while 82 added to existing stakes and 42 trimmed.

The largest buyer was Waddell & Reed Financial, opening a new position worth an estimated $39.9M. The largest seller was Viking Global Investors, cutting an estimated $112M.

  • 195 institutional investors held Kite Pharma, Inc. (KITE) as of Q3 2016, up from 173 in Q2 2016.
  • Funds reported $2.15B of Kite Pharma, Inc. stock for Q3 2016, up 14% quarter-over-quarter.
  • 43 funds opened new Kite Pharma, Inc. positions in Q3 2016 and 19 closed out, a net change of +24 holders.
  • The largest Kite Pharma, Inc. buyer in Q3 2016 was Waddell & Reed Financial, an estimated $39.9M added.
  • The largest Kite Pharma, Inc. seller in Q3 2016 was Viking Global Investors, an estimated $112M sold.

Based on aggregated 13F filings for Q3 2016.